Swedish Orphan Biovitrum AB (publ) (SOBIS.XC)
- Previous Close
264.90 - Open
264.90 - Bid 264.80 x --
- Ask 282.40 x --
- Day's Range
264.90 - 264.90 - 52 Week Range
185.25 - 290.60 - Volume
478 - Avg. Volume
13 - Market Cap (intraday)
95.503B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
41.85 - EPS (TTM)
6.33 - Earnings Date Jul 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
www.sobi.com1,752
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SOBIS.XC
Performance Overview: SOBIS.XC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SOBIS.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SOBIS.XC
Valuation Measures
Market Cap
95.50B
Enterprise Value
114.20B
Trailing P/E
41.91
Forward P/E
27.17
PEG Ratio (5yr expected)
1.71
Price/Sales (ttm)
3.82
Price/Book (mrq)
2.51
Enterprise Value/Revenue
4.94
Enterprise Value/EBITDA
15.65
Financial Highlights
Profitability and Income Statement
Profit Margin
9.26%
Return on Assets (ttm)
4.51%
Return on Equity (ttm)
6.72%
Revenue (ttm)
23.14B
Net Income Avi to Common (ttm)
2.14B
Diluted EPS (ttm)
6.33
Balance Sheet and Cash Flow
Total Cash (mrq)
527M
Total Debt/Equity (mrq)
53.54%
Levered Free Cash Flow (ttm)
2.69B
Company Insights: SOBIS.XC
SOBIS.XC does not have Company Insights